US5451205A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Facilitated oxygen delivery in conjunction with hemodilution
Assignee: PFC Therapeutics LLC
•
Filing: 1994-06-03
•
Granted: 1995-09-19
•
Expires: 2014-06-03
Abstract
Abstract A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier.
Inventors
- 👤 Duane J. Roth
- 👤 Peter E. Keipert
- 👤 Nicholas S. Faithfull
- 👤 Thomas F. Zuck
- 👤 Jean G. Riess
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 15:34
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/02; A61K38/00; A61K38/16; A61K38/41; A61K38/42; A61M; A61M1/00; A61M1/02; A61P; A61P7/00; A61P7/08; A61M2202/00; A61M2202/04; A61M2202/0468; A61M2202/0476
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
79 words
A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of: removing and maintaining a portion of the patient's blood; intravenously administering an effective oxygen delivery-enhancing amount of a synthetic biocompatible oxygen carrier; having said patient undergo a loss of blood subsequent to the administration of the oxygen carrier; administering breathing gas comprising 50%-100% oxygen to said patient during said loss of blood; and readministering said maintained blood to said patient.
Claim 2
Independent Claim
79 words
A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of: removing and maintaining a portion of the patient's blood; intravenously administering an effective oxygen delivery-enhancing amount of a synthetic biocompatible oxygen carrier; having said patient undergo a loss of blood subsequent to the administration of the oxygen carrier; administering breathing gas comprising 50%-100% oxygen to said patient during said loss of blood; and readministering said maintained blood to said patient.
Claim 3
Dependent Claim
31 words
The method of claim 1, further comprising the step of administering an effective cardiac output-increasing amount of a hemodiluent separately from said oxygen carrier in conjunction with said loss of blood.
Claim 4
Dependent Claim
16 words
The method of claim 2, wherein said hemodiluent is a crystalloid, colloid, or a combination thereof.
Claim 5
Dependent Claim
18 words
The method of claim 1, wherein the oxygen carrier is derived from human, animal, plant or recombinant hemoglobin.
Claim 6
Dependent Claim
13 words
The method of claim 1, wherein the oxygen carrier is a fluorocarbon emulsion.
Claim 7
Dependent Claim
27 words
The method of claim 1, wherein the amount of said oxygen carrier administered is no more than 3 g/kg, based on the body weight of the patient.
Claim 8
Dependent Claim
13 words
The method of claim 1, wherein said blood loss is associated with surgery.
Claim 9
Dependent Claim
25 words
The method of claim 7, further comprising the step of administering an additional amount of a biocompatible synthetic oxygen carrier to said patient during surgery.
Claim 10
Dependent Claim
13 words
The method of claim 1, wherein said blood loss is associated with trauma.
Claim 11
Dependent Claim
19 words
The method of claim 1, wherein said oxygen carrier further includes an effective cardiac output-increasing amount of a hemodiluent.
Claim 12
Independent Claim
91 words
A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of: removing and maintaining a portion of the patient's blood; intravenously administering an effective cardiac output-increasing amount of a hemodiluent in conjunction with a surgical procedure involving a loss of blood; intravenously administering an effective oxygen delivery-enhancing amount of a synthetic biocompatible oxygen carrier in conjunction with said blood loss; administering breathing gas comprising 50%-100% oxygen to said patient during said loss of blood; and then readministering said maintained blood to said patient.
Claim 13
Independent Claim
91 words
A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of: removing and maintaining a portion of the patient's blood; intravenously administering an effective cardiac output-increasing amount of a hemodiluent in conjunction with a surgical procedure involving a loss of blood; intravenously administering an effective oxygen delivery-enhancing amount of a synthetic biocompatible oxygen carrier in conjunction with said blood loss; administering breathing gas comprising 50%-100% oxygen to said patient during said loss of blood; and then readministering said maintained blood to said patient.
Claim 14
Dependent Claim
19 words
The method of claim 11, wherein said synthetic oxygen carrier is derived from human, animal, plant or recombinant hemoglobin.
Claim 15
Dependent Claim
13 words
The method of claim 11, wherein the oxygen carrier is a fluorocarbon emulsion.
Claim 16
Dependent Claim
27 words
The method of claim 11, wherein the amount of said oxygen carrier administered is no more than 3 g/kg, based on the body weight of the patient.
Claim 17
Dependent Claim
16 words
The method of claim 11, wherein said hemodiluent is a crystalloid, colloid, or a combination thereof.
Claim 18
Dependent Claim
27 words
The method of claim 11, further comprising the step of administering an additional amount of a biocompatible synthetic oxygen carrier to said patient during said surgical procedure.
Claim 19
Independent Claim
126 words
A method for facilitating autologous blood use by a patient facing a loss of blood during surgery, comprising the steps of: removing and extracorporeally maintaining a portion of the patient's blood; intravenously administering a hemodiluent to said patient in conjunction with the removing step in a volume at least as great as the volume of blood removed, thereby increasing the cardiac output of the patient; thereafter initiating a surgical procedure on said patient, said surgical procedure involving a loss of blood; administering an effective oxygen delivery-enhancing amount, but no more than 3 g/kg, of a biocompatible synthetic oxygen carrier to said patient in conjunction with said surgical procedure; and administering a breathing gas to said patient during said surgical procedure, said breathing gas comprising 50%-100% oxygen.
Claim 20
Independent Claim
126 words
A method for facilitating autologous blood use by a patient facing a loss of blood during surgery, comprising the steps of: removing and extracorporeally maintaining a portion of the patient's blood; intravenously administering a hemodiluent to said patient in conjunction with the removing step in a volume at least as great as the volume of blood removed, thereby increasing the cardiac output of the patient; thereafter initiating a surgical procedure on said patient, said surgical procedure involving a loss of blood; administering an effective oxygen delivery-enhancing amount, but no more than 3 g/kg, of a biocompatible synthetic oxygen carrier to said patient in conjunction with said surgical procedure; and administering a breathing gas to said patient during said surgical procedure, said breathing gas comprising 50%-100% oxygen.
Claim 21
Dependent Claim
20 words
The method of claim 17, wherein said synthetic oxygen carrier is a fluorocarbon in the form of a fluorocarbon emulsion.
Claim 22
Dependent Claim
12 words
The method of claim 17, wherein said synthetic oxygen carrier is hemoglobin.
Claim 23
Dependent Claim
17 words
The method of claim 17, further comprising the step of readministering said maintained blood to said patient.
References Cited (Backward Citations)
US3482575A
Cited
US3975512A
Cited
US4073879A
Cited
US4275726A
Cited
US4301144A
Cited
US4981691A
Cited
US4777244A
Cited
US4473494A
Cited
US4698387A
Cited
US4526715A
Cited
US4600531A
Cited
US4963130A
Cited
EP0231070A2
Cited
US4927623A
Cited
US4987154A
Cited
US5080885A
Cited
US4911929A
Cited
US4861867A
Cited
US5130230A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-09-18 | 1999-03-20 | 1999-09-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-09-18 | 2003-03-20 | 2003-09-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-09-18 | 2007-03-20 | 2007-09-19 | $7700.00 | Window Closed / Lapsed |